Hiroshi Fukumitsu
Tokai University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hiroshi Fukumitsu.
Gastroenterology | 2009
Reiichi Higashiyama; Tadashi Moro; Sachie Nakao; Kenichiro Mikami; Hiroshi Fukumitsu; Yoshitaka Ueda; Kazuo Ikeda; Eijiro Adachi; George Bou–Gharios; Isao Okazaki; Yutaka Inagaki
BACKGROUND & AIMS Recent studies have reported that bone marrow (BM)-derived cells migrating into fibrotic liver tissue exhibit a myofibroblast-like phenotype and may participate in the progression of liver fibrosis. However, their contribution to collagen production has not been fully verified yet. We revisited this issue by using 2 mechanistically distinct liver fibrosis models introduced into transgenic collagen reporter mice and their BM recipients. METHODS BM of wild-type mice was replaced by cells obtained from transgenic animals harboring tissue-specific enhancer/promoter sequences of alpha2(I) collagen gene (COL1A2) linked to enhanced green fluorescent protein (EGFP) or firefly luciferase (LUC) gene. Liver fibrosis was introduced into those mice by repeated carbon tetrachloride injections or ligation of the common bile duct. Activation of COL1A2 promoter was assessed by confocal microscopic examination detecting EGFP signals and luciferase assays of liver homogenates. RESULTS The tissue-specific COL1A2 enhancer/promoter was activated in hepatic stellate cells following a single carbon tetrachloride injection or during primary culture on plastic. A large number of EGFP-positive collagen-expressing cells were observed in liver tissue of transgenic COL1A2/EGFP mice in both liver fibrosis models. In contrast, there were few EGFP-positive BM-derived collagen-producing cells detected in fibrotic liver tissue of COL1A2/EGFP recipients. Luciferase assays of liver tissues from COL1A2/LUC-recipient mice further indicated that BM-derived cells produced little collagen in response to fibrogenic stimuli. CONCLUSIONS By using a specific and sensitive experimental system, which detects exclusively BM-derived collagen-producing cells, we conclude an unexpectedly limited role of BM-derived cells in collagen production during hepatic fibrogenesis.
Journal of Investigative Dermatology | 2011
Reiichi Higashiyama; Sachie Nakao; Yayoi Shibusawa; Osamu Ishikawa; Tadashi Moro; Kenichiro Mikami; Hiroshi Fukumitsu; Yoshitaka Ueda; Kaori Minakawa; Yasuhiko Tabata; George Bou-Gharios; Yutaka Inagaki
Recent studies show that bone marrow (BM)-derived cells migrating into a dermal wound promote healing by producing collagen type I. However, their contribution to the repair process has not been fully verified yet. It is also unclear whether BM-derived cells participate in dermal fibrogenesis. We have addressed these issues using transgenic mice that harbor tissue-specific enhancer/promoter sequences of α2(I) collagen gene linked to either enhanced green fluorescent protein (COL/EGFP) or the luciferase (COL/LUC) reporter gene. Following dermal excision or subcutaneous bleomycin administration, a large number of EGFP-positive collagen-producing cells appeared in the dermis of COL/EGFP reporter mice. When wild-type mice were transplanted with BM cells from transgenic COL/EGFP animals and subjected to dermal excision, no EGFP-positive BM-derived collagen-producing cells were detected throughout the repair process. Luciferase assays of dermal tissues from COL/LUC recipient mice also excluded collagen production by BM-derived cells during dermal excision healing. In contrast, a limited but significant number of CD45-positive collagen-producing cells migrated from BM following bleomycin injection. These results indicate that resident cells in the skin are the major source of de novo collagen deposition in both physiological and pathological conditions, whereas BM-derived cells participate, in part, in collagen production during dermal fibrogenesis.
Stem Cells | 2018
Takayo Yanagawa; Hideaki Sumiyoshi; Kiyoshi Higashi; Sachie Nakao; Reiichi Higashiyama; Hiroshi Fukumitsu; Kaori Minakawa; Yosuke Chiba; Yuhei Suzuki; Kayo Sumida; Koichi Saito; Akihide Kamiya; Yutaka Inagaki
Granulocyte colony stimulating factor (G‐CSF) has been reported to ameliorate impaired liver function in patients with advanced liver diseases through mobilization and proliferation of hepatic progenitor cells (HPCs). However, the underlying mechanisms remain unknown. We previously showed that G‐CSF treatment increased the number of bone marrow (BM)‐derived cells migrating to the fibrotic liver following repeated carbon tetrachloride (CCl4) injections into mice. In this study, we identified opioid growth factor receptor‐like 1 (OGFRL1) as a novel BM cell‐derived accelerator of fibrotic liver regeneration in response to G‐CSF treatment. Endogenous Ogfrl1 was highly expressed in the hematopoietic organs such as the BM and spleen, whereas the liver contained a relatively small amount of Ogfrl1 mRNA. Among the peripheral blood cells, monocytes were the major sources of OGFRL1. Endogenous Ogfrl1 expression in both the peripheral blood monocytes and the liver was decreased following repeated CCl4 injections. An intrasplenic injection of cells overexpressing OGFRL1 into CCl4‐treated fibrotic mice increased the number of HPC and stimulated proliferation of hepatic parenchymal cells after partial resection of the fibrotic liver. Furthermore, overexpression of OGFRL1 in cultured HPC accelerated their differentiation as estimated by increased expression of liver‐specific genes such as hepatocyte nuclear factor 4α, cytochrome P450, and fatty acid binding protein 1, although it did not affect the colony forming ability of HPC. These results indicate a critical role of OGFRL1 in the mobilization and differentiation of HPC in the fibrotic liver, and administration of OGFRL1‐expressing cells may serve as a potential regenerative therapy for advanced liver fibrosis. Stem Cells 2019;37:89–101
The Tokai journal of experimental and clinical medicine | 2001
Seiei Yasuda; Tatsuhiko Hoshikawa; Naoki Yazawa; Hiroshi Fukumitsu; Kenji Ishikawa; Toshiyuki Suzuki; Sotaro Sadahiro; Yasuhito Shimakura; Makoto Shibuya; Seiji Nasu; Tomoo Tajima; Hiroyasu Makuuchi
Oncology Reports | 2009
Masaya Mukai; Kazutake Okada; Hiroshi Fukumitsu; Naoki Yazawa; Tatsuhiko Hoshikawa; Takayuki Tajima; Hitoshi Hirakawa; Kyouji Ogoshi; Hiroyasu Makuuchi
Oncology Reports | 1994
Masaya Mukai; Maki Fukasawa; Kyoko Kishima; Shin-Ichi Iizuka; Hiroshi Fukumitsu; Naoki Yazawa; Takayuki Tajima; Masato Nakamura; Hiroyasu Makuuchi
Oncology Letters | 2011
Masaya Mukai; Yasutomo Sekido; Hiroshi Fukumitsu; Hideki Izumi; Tatsuhiko Hoshikawa; Takayuki Tajima; Kousuke Tobita; Sotaro Sadahiro; Seiei Yasuda; Kyoji Ogoshi
The Japanese Journal of Gastroenterological Surgery | 2010
Takayuki Tajima; Masaya Mukai; Maki Fukasawa; Naoki Yazawa; Hiroshi Fukumitsu; Masato Nakamura; Hiroyasu Makuuchi
Oncology Reports | 2010
Masaya Mukai; Yasutomo Sekido; Tatsuhiko Hoshikawa; Naoki Yazawa; Hiroshi Fukumitsu; Kazutake Okada; Takayuki Tajima; Masato Nakamura; Kyouji Ogoshi
Oncology Reports | 2009
Masaya Mukai; Kyoko Kishima; Takayuki Tajima; Tatsuhiko Hoshikawa; Naoki Yazawa; Hiroshi Fukumitsu; Kazutake Okada; Kyouji Ogoshi; Hiroyasu Makuuchi